~ Buy the ZELSUVMI (berdazimer sodium) Drug Profile, 2024 PDF Report in the Report Store ~

ZELSUVMI Drug Patent Profile

✉ Email this page to a colleague

When do Zelsuvmi patents expire, and what generic alternatives are available?

Zelsuvmi is a drug marketed by Lnhc and is included in one NDA. There are fourteen patents protecting this drug.

This drug has fifty-eight patent family members in nine countries.

The generic ingredient in ZELSUVMI is berdazimer sodium. Additional details are available on the berdazimer sodium profile page.

DrugPatentWatch^® Generic Entry Outlook for Zelsuvmi

Zelsuvmi will be eligible for patent challenges on January 5, 2028. This date may extended up to six months if a pediatric exclusivity extension is applied to the drug's patents.

By analyzing the patents and regulatory protections it appears that the earliest date for generic entry will be January 5, 2029. This may change due to patent challenges or generic licensing.

Indicators of Generic Entry

< Available with Subscription >

Sign Up

AI Research Assistant

Questions you can ask:

What is the 5 year forecast for ZELSUVMI?
What are the global sales for ZELSUVMI?
What is Average Wholesale Price for ZELSUVMI?

Summary for ZELSUVMI

International Patents:	58
US Patents:	14
Applicants:	1
NDAs:	1
DailyMed Link:	ZELSUVMI at DailyMed

Drug patent expirations by year for ZELSUVMI

DrugPatentWatch^® Estimated Loss of Exclusivity (LOE) Date for ZELSUVMI

Generic Entry Date for ZELSUVMI^: ⤷ Sign Up* Constraining patent/regulatory exclusivity: NEW CHEMICAL ENTITY NDA: 217424 Dosage: GEL;TOPICAL

^*The generic entry opportunity date is the latter of the last compound-claiming patent and the last regulatory exclusivity protection. Many factors can influence early or later generic entry. This date is provided as a rough estimate of generic entry potential and should not be used as an independent source.

US Patents and Regulatory Information for ZELSUVMI

ZELSUVMI is protected by twenty-two US patents and one FDA Regulatory Exclusivity.

Based on analysis by DrugPatentWatch, the earliest date for a generic version of ZELSUVMI is ⤷ Sign Up.

This potential generic entry date is based on NEW CHEMICAL ENTITY.
Generics may enter earlier, or later, based on new patent filings, patent extensions, patent invalidation, early generic licensing, generic entry preferences, and other factors.

Patents protecting ZELSUVMI

Topical compositions and methods of using the same
Patent Number: ⤷ Sign Up
Patent Expiration: ⤷ Sign Up
Patented Use: METHOD OF TOPICALLY REDUCING LESIONS WITH TWO SEPARATELY STORED COMPONENTS

Anhydrous compositions
Patent Number: ⤷ Sign Up
Patent Expiration: ⤷ Sign Up

Topical antiviral compositions and methods of using the same
Patent Number: ⤷ Sign Up
Patent Expiration: ⤷ Sign Up
Patented Use: METHOD OF ADMINISTERING A NITRIC OXIDE RELEASING API IN A COMBINATION TOPICAL COMPOSITION

Topical antiviral compositions and methods of using the same
Patent Number: ⤷ Sign Up
Patent Expiration: ⤷ Sign Up
Patented Use: METHOD OF TREATING AND/OR PREVENTING VIRAL INFECTION WITH A TOPICAL COMPOSITION INCLUDING A NITRIC OXIDE RELEASING API

Topical antiviral compositions and methods of using the same
Patent Number: ⤷ Sign Up
Patent Expiration: ⤷ Sign Up
Patented Use: METHOD OF TREATING AND/OR PREVENTING MOLLUSCUM CONTAGIOSUM WITH A TOPICAL COMPOSITION INCLUDING A NITRIC OXIDE RELEASING API

Topical antiviral compositions and methods of using the same
Patent Number: ⤷ Sign Up
Patent Expiration: ⤷ Sign Up
Patented Use: METHOD OF PREVENTING AND/OR REDUCING APPEARANCE AND/OR SIZE OF MALIGNANT LESION WITH A TOPICAL COMPOSITION INCLUDING A NITRIC OXIDE RELEASING API

Topical gels and methods of using the same
Patent Number: ⤷ Sign Up
Patent Expiration: ⤷ Sign Up

Topical antiviral compositions, delivery systems, and methods of using the same
Patent Number: ⤷ Sign Up
Patent Expiration: ⤷ Sign Up
Patented Use: METHOD OF TREATING AND/OR PREVENTING MOLLUSCUM CONTAGIOSUM WITH A NITRIC OXIDE RELEASING TOPICAL COMPOSITION

Topical antiviral compositions, delivery systems, and methods of using the same
Patent Number: ⤷ Sign Up
Patent Expiration: ⤷ Sign Up
Patented Use: METHOD OF TREATING, PREVENTING, OR REDUCING LESIONS CAUSED BY MOLLUSCUM CONTAGIOSUM

Topical antiviral compositions, delivery systems, and methods of using the same
Patent Number: ⤷ Sign Up
Patent Expiration: ⤷ Sign Up
Patented Use: METHOD OF TREATING AND/OR PREVENTING VIRAL INFECTION WITH A TOPICAL NITRIC OXIDE RELEASING COMPONENT

Topical antiviral compositions, delivery systems, and methods of using the same
Patent Number: ⤷ Sign Up
Patent Expiration: ⤷ Sign Up
Patented Use: METHOD OF TREATING AND/OR PREVENTING VIRAL INFECTION USING A NITRIC OXIDE RELEASING ACTIVE INGREDIENT

Topical compositions and methods of using the same
Patent Number: ⤷ Sign Up
Patent Expiration: ⤷ Sign Up

Patent Number: ⤷ Sign Up
Patent Expiration: ⤷ Sign Up
Patented Use: METHOD OF ADMINISTERING A NITRIC OXIDE RELEASING ACTIVE PHARMACEUTICAL INGREDIENT TO TREAT AND/OR PREVENT VIRAL INFECTION

Nitric oxide-releasing particles for nitric oxide therapeutics and biomedical applications
Patent Number: ⤷ Sign Up
Patent Expiration: ⤷ Sign Up

Topical compositions
Patent Number: ⤷ Sign Up
Patent Expiration: ⤷ Sign Up
Patented Use: METHOD OF APPLICATION OF TOPICAL PHARMACEUTICAL COMPOSITION TO TREAT DERMATOLOGICAL CONDITION

Topical gels and methods of using the same
Patent Number: ⤷ Sign Up
Patent Expiration: ⤷ Sign Up

Topical gels and methods of using the same
Patent Number: ⤷ Sign Up
Patent Expiration: ⤷ Sign Up
Patented Use: METHOD OF TREATING SKIN AILMENT WITH NITRIC OXIDE RELEASING MACROMOLECULES AND HYDROPHILIC GEL

Topical compositions and methods of using the same
Patent Number: ⤷ Sign Up
Patent Expiration: ⤷ Sign Up
Patented Use: METHOD OF APPLYING RELEASED NITRIC OXIDE TO SKIN FROM COMBINATION INCLUDING ANHYDROUS ALCOHOL GEL

Topical compositions and methods of using the same
Patent Number: ⤷ Sign Up
Patent Expiration: ⤷ Sign Up
Patented Use: METHOD OF INCREASING RELEASE OF NITRIC OXIDE FROM ANHYDROUS ALCOHOL GEL

FDA Regulatory Exclusivity protecting ZELSUVMI

NEW CHEMICAL ENTITY
Exclusivity Expiration: ⤷ Sign Up

+ Get email alerts for changes to this table

Glossary

Subscribe to access the full database, or Sign Up
Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	TE	Type	RLD	RS	Patent No.	Patent Expiration	Product	Substance	Delist Req.	Exclusivity Expiration
Lnhc	ZELSUVMI	berdazimer sodium	GEL;TOPICAL	217424-001	Jan 5, 2024		RX	Yes	Yes	⤷ Sign Up	⤷ Sign Up	Y			⤷ Sign Up
Lnhc	ZELSUVMI	berdazimer sodium	GEL;TOPICAL	217424-001	Jan 5, 2024		RX	Yes	Yes	⤷ Sign Up	⤷ Sign Up		Y		⤷ Sign Up
Lnhc	ZELSUVMI	berdazimer sodium	GEL;TOPICAL	217424-001	Jan 5, 2024		RX	Yes	Yes	⤷ Sign Up	⤷ Sign Up	Y			⤷ Sign Up
Lnhc	ZELSUVMI	berdazimer sodium	GEL;TOPICAL	217424-001	Jan 5, 2024		RX	Yes	Yes	⤷ Sign Up	⤷ Sign Up	Y			⤷ Sign Up
Lnhc	ZELSUVMI	berdazimer sodium	GEL;TOPICAL	217424-001	Jan 5, 2024		RX	Yes	Yes	⤷ Sign Up	⤷ Sign Up	Y			⤷ Sign Up
Lnhc	ZELSUVMI	berdazimer sodium	GEL;TOPICAL	217424-001	Jan 5, 2024		RX	Yes	Yes	⤷ Sign Up	⤷ Sign Up				⤷ Sign Up
>Applicant	>Tradename	>Generic Name	>Dosage	>NDA	>Approval Date	>TE	>Type	>RLD	>RS	>Patent No.	>Patent Expiration	>Product	>Substance	>Delist Req.	>Exclusivity Expiration

International Patents for ZELSUVMI

See the table below for patents covering ZELSUVMI around the world.

Subscribe to access the full database, or Sign Up
Country	Patent Number	Title	Estimated Expiration
Canada	2771308	GELS TOPIQUES (TOPICAL GELS)	⤷ Sign Up
China	105392472	Topical compositions and methods of using the same	⤷ Sign Up
South Korea	102495101		⤷ Sign Up
World Intellectual Property Organization (WIPO)	2011022652		⤷ Sign Up
European Patent Office	3698775	COMPOSITIONS ANTIVIRALES TOPIQUES ET MÉTHODES D'UTILISATION (TOPICAL ANTIVIRAL COMPOSITIONS AND METHODS OF USING THE SAME)	⤷ Sign Up
Canada	2900557	COMPOSITIONS TOPIQUES ET LEURS PROCEDES D'UTILISATION (TOPICAL COMPOSITIONS AND METHODS OF USING THE SAME)	⤷ Sign Up
>Country	>Patent Number	>Title	>Estimated Expiration